Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Monday that its third quarter revenues skyrocketed 300 percent year over year due to growth in the firm's DecisionDx- Melanoma test report volume.

For the three months ended Sept. 30, the skin cancer test developer reported total revenues of $14.8 million, up from $3.7 million during the same period a year earlier and beating analysts' average estimate of $9.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.